This Article Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fürnsinn, C. Articles by Vierhapper, H. Search for Related Content PubMed PubMed Citation Articles by Fürnsinn, C. Articles by Vierhapper, H.

Thiazolidinediones Influence Plasma Steroids of Male Obese Zucker Rats

Department of Medicine III, Division of Endocrinology & Metabolism, University of Vienna, A-1090 Vienna, Austria

Address all correspondence and requests for reprints to: Clemens Fürnsinn, Ph.D., University of Vienna, Department of Medicine III, Division of Endocrinology and Metabolism, Wahringer Gurtel 18-20, Vienna A-1090, Austria.

Insulin sensitizing thiazolidinediones (TZDs) inhibit steroidogenic enzyme activities in vitro and affect plasma steroids in women with polycystic ovary syndrome. This study was to examine TZD action on circulating steroids in male genetically obese Zucker rats (fa/fa), which were treated with troglitazone or rosiglitazone (0.3% and 0.01% food admixture, respectively) and were compared to untreated obese and lean littermates. After 36 days of TZD administration, obesity- associated derangement of carbohydrate metabolism was ameliorated (e.g., insulin-stimulated glucose oxidation by isolated soleus muscle, nmol/g/h: lean controls, 1049 ± 100; obese controls, 518 ± 30; troglitazone-treated obese, 672 ± 43; rosiglitazone-treated obese, 761 ± 77; p < 0.01 each vs. obese controls). While plasma pregnenolone and testosterone were neither affected by obesity nor by TZDs, a marked reduction of 17-hydroxyprogesterone in obese vs. lean controls (27 ± 3 vs. 58 ± 10 ng/dl; p < 0.01) was partially reversed by TZD treatment (46 ± 5 and 48 ± 9 ng/dl for troglitazone and rosiglitazone, respectively; p < 0.02 each vs. untreated obese). Plasma 5--dihydrotestosterone, in contrast, was not reduced by obesity (76 ± 9 vs. 59 ± 7 ng/dl in obese vs. lean controls; n.s.) but blunted by TZD treatment of obese rats (38 ± 4 and 44 ± 3 ng/dl for troglitazone and rosiglitazone, respectively; p < 0.05 each vs. untreated obese). We conclude that (i) oral TZD treatment influences circulating steroid concentrations of male obese Zucker rats, and (ii) these effects are at least in part mediated via mechanisms other than those underlying TZD-induced insulin sensitization.

This article has been cited by other articles:

				M. Jensterle, A. Janez, B. Mlinar, J. Marc, J. Prezelj, and M. Pfeifer Impact of metformin and rosiglitazone treatment on glucose transporter 4 mRNA expression in women with polycystic ovary syndrome. Eur. J. Endocrinol., June 1, 2008; 158(6): 793 - 801. [Abstract] [Full Text] [PDF]

				V. Sepilian and M. Nagamani Effects of Rosiglitazone in Obese Women with Polycystic Ovary Syndrome and Severe Insulin Resistance J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 60 - 65. [Abstract] [Full Text] [PDF]